MRI biomarkers in Huntington's disease.

Huntington's disease (HD) is a devastating neurodegenerative disease affecting the brain resulting in neuronal dysfunction and neuronal loss. Since the identification of the gene responsible for HD, genetic testing has become widely available, allowing for genetic status of persons at risk for HD to be determined. For the effective evaluation of future therapeutic trials a great need exists for sensitive biomarkers. In (premanifest) HD, MRI of the brain is one of the most logical candidates as a biomarker, as opposed to clinical measures, since brain neurons are the main target of the disease. These biomarkers can facilitate early detection of disease related changes, but are also needed to monitor disease progression from the premanifest phase of HD onwards. MRI derived parameters have this biomarker potential as they have been shown to identify brain abnormalities before symptom onset. In this review the available MRI techniques of conventional MRI, Diffusion Tensor Imaging, Magnetization Transfer Imaging, Magnetic Resonance Spectroscopy and Functional MRI will be discussed and the findings will be placed into context of different HD stages.

[1]  B D Ross,et al.  Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases , 1998, Neurology.

[2]  G. Pearlson,et al.  Frontal lobe volume in patients with Huntington's disease , 1998, Neurology.

[3]  Timothy Edward John Behrens,et al.  In vivo evidence for the selective subcortical degeneration in Huntington's disease , 2009, NeuroImage.

[4]  D. Brooks,et al.  Evidence for glutamate excitotoxicity in Huntington's disease with proton magnetic resonance spectroscopy , 1994, The Lancet.

[5]  E. Vandenbussche,et al.  Cognitive changes in patients with Huntington’s disease (HD) and asymptomatic carriers of the HD mutation , 2004, Journal of Neurology.

[6]  Jeroen van der Grond,et al.  Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease , 2012, Human brain mapping.

[7]  R. Reilmann,et al.  Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease , 2010, Neurology.

[8]  Jan Kassubek,et al.  Thalamic atrophy in Huntington's disease co-varies with cognitive performance: a morphometric MRI analysis. , 2005, Cerebral cortex.

[9]  Jane S. Paulsen,et al.  White Matter Volume and Cognitive Dysfunction in Early Huntington's Disease , 2005, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.

[10]  J Kassubek,et al.  Topography of cerebral atrophy in early Huntington’s disease: a voxel based morphometric MRI study , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[11]  G Hör,et al.  Multimodal imaging of residual function and compensatory resource allocation in cortical atrophy: a case study of parietal lobe function in a patient with Huntington's disease. , 1998, Psychiatry research.

[12]  E. Tolosa,et al.  Decreased frontal choline and neuropsychological performance in preclinical Huntington disease , 2007, Neurology.

[13]  Sarah A. J. Reading,et al.  Functional brain changes in presymptomatic Huntington's disease , 2004, Annals of neurology.

[14]  Nick C Fox,et al.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data , 2009, The Lancet Neurology.

[15]  R. Roos,et al.  Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington's disease. , 2010, Parkinsonism & related disorders.

[16]  Kurt E. Weaver,et al.  Longitudinal diffusion tensor imaging in Huntington's Disease , 2009, Experimental Neurology.

[17]  A. Dale,et al.  Regional and progressive thinning of the cortical ribbon in Huntington’s disease , 2002, Neurology.

[18]  J. Brandt,et al.  Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at‐risk persons , 1994, Neurology.

[19]  R. E. Steiner,et al.  Clinical NMR imaging of the brain: 140 cases , 1982 .

[20]  Anne-Catherine Bachoud-Lévi,et al.  Distribution of grey matter atrophy in Huntington’s disease patients: A combined ROI-based and voxel-based morphometric study , 2006, NeuroImage.

[21]  A. Ludolph,et al.  Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[22]  C. Hanstock,et al.  Is brain lactate increased in Huntington's disease? , 2007, Journal of the Neurological Sciences.

[23]  Jane S. Paulsen,et al.  fMRI detection of early neural dysfunction in preclinical Huntington's disease , 2007, Journal of the International Neuropsychological Society.

[24]  L. Raymond,et al.  Caudate volume as an outcome measure in clinical trials for Huntington’s disease: a pilot study , 2003, Brain Research Bulletin.

[25]  Anusha Sritharan,et al.  Increased cortical recruitment in Huntington's disease using a Simon task , 2007, Neuropsychologia.

[26]  Sarah A. J. Reading,et al.  Functional MRI study of a serial reaction time task in Huntington's disease , 2004, Psychiatry Research: Neuroimaging.

[27]  B Fischl,et al.  Regional cortical thinning in preclinical Huntington disease and its relationship to cognition , 2005, Neurology.

[28]  J. Marinus,et al.  Autonomic symptoms in patients and pre‐manifest mutation carriers of Huntington’s disease , 2010, European journal of neurology.

[29]  Mario Mascalchi,et al.  Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. , 2004, Radiology.

[30]  Hans J. Johnson,et al.  Cerebral cortex structure in prodromal Huntington disease , 2010, Neurobiology of Disease.

[31]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[32]  C D Good,et al.  The distribution of structural neuropathology in pre-clinical Huntington's disease. , 2002, Brain : a journal of neurology.

[33]  V. Clark,et al.  Altered functional MRI responses in Huntington's disease , 2002, Neuroreport.

[34]  Jane S. Paulsen,et al.  Diffusion Tensor Imaging in Preclinical Huntington’s Disease , 2009, Brain Imaging and Behavior.

[35]  Daniel Ecker,et al.  Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI. , 2007, Brain : a journal of neurology.

[36]  C. Terrence,et al.  Computed tomography for Huntington's disease , 1977, Neuroradiology.

[37]  Terry L. Jernigan,et al.  Cerebral structure on MRI, part II: Specific changes in Alzheimer's and Huntington's diseases , 1991, Biological Psychiatry.

[38]  Jane S. Paulsen,et al.  CAG‐repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[39]  Stefan Klöppel,et al.  White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. , 2008, Brain : a journal of neurology.

[40]  N Makris,et al.  Striatal volume loss in HD as measured by MRI and the influence of CAG repeat , 2001, Neurology.

[41]  L. Bäckman,et al.  Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. , 1997, Brain : a journal of neurology.

[42]  Mark Mühlau,et al.  Striatal gray matter loss in Huntington's disease is leftward biased , 2007, Movement disorders : official journal of the Movement Disorder Society.

[43]  F. Cendes,et al.  Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat. , 2006, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[44]  Jane S. Paulsen,et al.  fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease. , 2004, AJNR. American journal of neuroradiology.

[45]  Jane S. Paulsen,et al.  Brain Structure in Preclinical Huntington’s Disease , 2006, Biological Psychiatry.

[46]  G. Pearlson,et al.  Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[47]  Jane S. Paulsen,et al.  In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease , 2004, Neurology.

[48]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[49]  B R Rosen,et al.  Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. , 1993, Neurology.

[50]  Jane S. Paulsen Functional imaging in Huntington's disease , 2009, Experimental Neurology.

[51]  Wilhelm Gaus,et al.  Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis , 2004, Neurology.

[52]  R. Barker,et al.  The current clinical management of Huntington's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[53]  R. Roos,et al.  Basal ganglia volume and clinical correlates in ‘preclinical’ Huntington’s disease , 2008, Journal of Neurology.

[54]  Frederik Maes,et al.  Diffusion-weighted versus volumetric imaging of the striatum in early symptomatic Huntington disease , 2009, Journal of Neurology.

[55]  F Cendes,et al.  Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[56]  Nick C. Fox,et al.  Rate and acceleration of whole‐brain atrophy in premanifest and early Huntington's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[57]  Nick C Fox,et al.  Relationship between CAG repeat length and brain volume in premanifest and early Huntington’s disease , 2009, Journal of Neurology.

[58]  J. Brandt,et al.  Impaired source memory in Huntington's disease and its relation to basal ganglia atrophy. , 1995, Journal of clinical and experimental neuropsychology.

[59]  Daniel Ecker,et al.  Cortical dysfunction in patients with Huntington's disease during working memory performance , 2009, Human brain mapping.

[60]  J. Caboche,et al.  Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments , 2008, Current opinion in neurology.

[61]  P. Sundgren,et al.  Magnetic resonance spectroscopy. , 2005, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[62]  Jane S. Paulsen,et al.  Detection of Huntington’s disease decades before diagnosis: the Predict-HD study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[63]  Massimo Filippi,et al.  Magnetization transfer magnetic resonance imaging of the brain, spinal cord, and optic nerve , 2007, Neurotherapeutics.

[64]  N. Georgiou-Karistianis,et al.  A peek inside the Huntington's brain: will functional imaging take us one step closer in solving the puzzle? , 2009, Experimental Neurology.

[65]  Jane S. Paulsen,et al.  Striatal and white matter predictors of estimated diagnosis for Huntington disease , 2010, Brain Research Bulletin.

[66]  M Filippi,et al.  Regional Distribution and Clinical Correlates of White Matter Structural Damage in Huntington Disease: A Tract-Based Spatial Statistics Study , 2010, American Journal of Neuroradiology.

[67]  G. Pearlson,et al.  Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. , 1996, Archives of neurology.

[68]  E. Tolosa,et al.  Prefrontal cortex volume reduction on MRI in preclinical Huntington's disease relates to visuomotor performance and CAG number. , 2009, Parkinsonism & related disorders.

[69]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[70]  Nick C Fox,et al.  Onset and Progression of Pathologic Atrophy in Huntington Disease: A Longitudinal MR Imaging Study , 2010, American Journal of Neuroradiology.

[71]  A. Blamire,et al.  High-dose creatine therapy for Huntington disease: A 2-year clinical and MRS study , 2005, Neurology.

[72]  R. V. D. Mast,et al.  Psychopathology in verified Huntington's disease gene carriers. , 2007, The Journal of neuropsychiatry and clinical neurosciences.

[73]  Sarah A. J. Reading,et al.  Regional white matter change in pre-symptomatic Huntington's disease: A diffusion tensor imaging study , 2005, Psychiatry Research: Neuroimaging.

[74]  Nick C Fox,et al.  Increased rate of whole-brain atrophy over 6 months in early Huntington disease , 2006, Neurology.

[75]  J. Bradshaw,et al.  Functional connectivity of the prefrontal cortex in Huntington’s disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[76]  Josephine Barnes,et al.  The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[77]  R. Roos,et al.  1H magnetic resonance spectroscopy in preclinical Huntington disease , 2007, Brain Research.

[78]  Sarah J Tabrizi,et al.  Huntington’s disease , 2010, BMJ : British Medical Journal.

[79]  R. Prost,et al.  Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease , 2005, Brain Research.

[80]  G. Pearlson,et al.  Longitudinal change in basal ganglia volume in patients with Huntington's disease , 1997, Neurology.

[81]  Nick C Fox,et al.  Whole‐brain atrophy as a measure of progression in premanifest and early Huntington's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[82]  C. Schönfeldt-Lecuona,et al.  Aberrant connectivity of lateral prefrontal networks in presymptomatic Huntington's disease , 2008, Experimental Neurology.

[83]  F. Cendes,et al.  Evidence of thalamic dysfunction in Huntington disease by proton magnetic resonance spectroscopy , 2007, Movement disorders : official journal of the Movement Disorder Society.

[84]  J. Willey,et al.  PRESTROKE PHYSICAL ACTIVITY IS ASSOCIATED WITH SEVERITY AND LONG-TERM OUTCOME FROM FIRST-EVER STROKE , 2009, Neurology.

[85]  Elizabeth H. Aylward,et al.  Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease , 2007, Brain Research Bulletin.

[86]  S. Folstein,et al.  Neuropsychological correlates of brain atrophy in Huntington's disease: a magnetic resonance imaging study , 1992, Neuroradiology.

[87]  Gordon J. Gilbert WEIGHT LOSS IN HUNTINGTON DISEASE INCREASES WITH HIGHER CAG REPEAT NUMBER , 2009 .

[88]  J. D. de Yébenes,et al.  Clinical correlation of striatal 1H MRS changes in Huntington’s disease , 1999, Neurology.

[89]  John L Bradshaw,et al.  A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[90]  J. Brandt,et al.  When does Huntington's disease begin? , 1998, Journal of the International Neuropsychological Society.

[91]  H. Diana Rosas,et al.  Neuroprotection for Huntington’s disease: Ready, set, slow , 2008, Neurotherapeutics.

[92]  A. Aron,et al.  Contrasting gray and white matter changes in preclinical Huntington disease , 2010, Neurology.

[93]  S. Folstein,et al.  Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease , 1992, Annals of neurology.

[94]  M. Battaglini,et al.  Magnetization Transfer MR Imaging Demonstrates Degeneration of the Subcortical and Cortical Gray Matter in Huntington Disease , 2010, American Journal of Neuroradiology.

[95]  J. Brandt,et al.  Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. , 1999, Brain : a journal of neurology.

[96]  Jeroen van der Grond,et al.  Magnetization transfer imaging in ‘premanifest’ Huntington’s disease , 2009, Journal of Neurology.

[97]  Jan Kassubek,et al.  Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: A neuropsychological and voxel-based morphometric study , 2005, Journal of the Neurological Sciences.

[98]  R. Reilmann,et al.  Creatine supplementation lowers brain glutamate levels in Huntington’s disease , 2005, Journal of Neurology.

[99]  B. Rosen,et al.  Evidence for irnnairment of energy metabofism in vivo in Huntington's disease using localized 1H NMR spectroscopy , 1993, Neurology.

[100]  C. Clarke,et al.  No change in striatal glutamate in Huntington's disease measured by proton magnetic resonance spectroscopy. , 1998, Parkinsonism & related disorders.

[101]  Peng Yu,et al.  Altered white matter microstructure in the corpus callosum in Huntington's disease: Implications for cortical “disconnection” , 2010, NeuroImage.

[102]  Nick C Fox,et al.  Pitfalls in the Use of Voxel-Based Morphometry as a Biomarker: Examples from Huntington Disease , 2010, American Journal of Neuroradiology.

[103]  R. C. Wolf,et al.  Funktionelle Bildgebung kognitiver Prozesse bei M.-Huntington-Patienten und präsymptomatischen Mutationsträgern , 2008, Der Nervenarzt.

[104]  Chris Frost,et al.  Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis , 2011, The Lancet Neurology.

[105]  Jane S. Paulsen,et al.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length , 2004, Clinical genetics.

[106]  J. Ashburner,et al.  Progression of structural neuropathology in preclinical Huntington’s disease: a tensor based morphometry study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[107]  Jeroen van der Grond,et al.  Early atrophy of pallidum and accumbens nucleus in Huntington’s disease , 2010, Journal of Neurology.

[108]  J. Brandt,et al.  Onset and rate of striatal atrophy in preclinical Huntington disease , 2004, Neurology.

[109]  Klaus Seppi,et al.  Diffusion‐weighted imaging in Huntington's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[110]  Bruce Fischl,et al.  Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. , 2008, Brain : a journal of neurology.

[111]  M. MacDonald,et al.  CAG repeat number governs the development rate of pathology in Huntington's disease , 1997, Annals of neurology.

[112]  D. Brooks,et al.  Proton magnetic resonance spectroscopy in Huntington's disease: Evidence in favour of the glutamate excitotoxic theory? , 1996, Movement disorders : official journal of the Movement Disorder Society.

[113]  B R Rosen,et al.  1H NMR spectroscopy studies of Huntington's disease , 1998, Neurology.

[114]  David S Tuch,et al.  Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures , 2006, Movement disorders : official journal of the Movement Disorder Society.

[115]  Jane S. Paulsen,et al.  Preparing for preventive clinical trials: the Predict-HD study. , 2006, Archives of neurology.

[116]  G. Barker,et al.  Proton MRS in Huntington's disease , 1994, The Lancet.